Option chain shows key data for Bullfrog AI Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bullfrog AI Hldgs.

Bullfrog AI Hldgs (NASDAQ:BFRG) Stock, Option Chain

Bullfrog AI Hldgs

Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.

Bernie's Concerns With Healthcare Costs

News

Short Ideas

Markets

Trading Ideas

BFRG

DOCS

GILD

GNFT

Top 4 Health Care Stocks That May Keep You Up At Night

Penny Stocks

Small Cap

Intraday Update

Movers

ALGM

ASST

BOOT

BRTX

CACC

CELU

CHRW

CMAX

CMND

CMPR

CTVA

DGII

EGHT

ELAB

ELWS

ETSY

EVAX

EVER

FBLG

FCEL

HSAI

IFBD

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MINM

NRBO

NVIV

NYCB

OGEN

PLUG

PSNY

PTON

RACE

REVB

RKLB

SPWR

SRDX

TCRT

VLCN

WOLF

YOSH

ZION

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

NVVE

RNAZ

TRIB

TROO

Shares of  Nextracker Inc. (NASDAQ: NXT) rose sharply during today’s pre-market trading after the company reported better-than-expected thi

Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Bullfrog AI Holdings, Inc. - Common Stock

Bullfrog AI Holdings Inc

NMHIW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

APLM

Apollomics shares are trading lower after the company announced a 1-for-100 reverse stock split.

Cantor Fitzgerald analyst Yi Fu Lee reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and maintains $445 price target.

Price Target

Reiteration

Analyst Ratings

PANW

Cantor Fitzgerald Reiterates Overweight on Palo Alto Networks, Maintains $445 Price Target

The International Criminal Court on Thursday issued arrest warrants for Israeli Prime Minister Benjamin Netanyahu and former defense minister Yoav Gallant, "for crimes against humanity and war crimes" in the <a href="https://www.benzinga.com/markets/emerging-markets/24/11/41757546/israels-netanyahu-fires-defense-minister-gallant-over-lack-of-trust-in-war-management-oi">ongoing war in Gaza</a>.
Netanyahu and Gallant intentionally deprived civilians in Gaza of food, water and medicine and medical supplies, as well as fuel and electricity, and used starvation as a method of warfare, the International Criminal Court alleges. 
The arrest warrants also allege both men deprived civilians in Gaza of fundamental rights, including the rights to life and health, and intentionally directed attacks against the civilian population of Gaza. The ICC&#8217;s Pre-trial Chamber I also found Netanyahu and Gallant are responsible for other inhumane acts. 
Israeli President Isaac Herzog called the arrest warrants a &#8220;dark day for justice&#8221; in a post on X, adding that the warrants are a &#8220;mockery&#8221; of those who fight for justice and &#8220;ignore the plight of the 101 Israeli hostages held in brutal captivity by Hamas in Gaza.&#8221; 
Herzog concluded: &#8220;This cynical exploitation of the international legal institutions reminds us once again of the need for true moral clarity in the face of an Iranian empire of evil that seeks to destabilize our region and the world, and destroy the very institutions of the free world.&#8221;
The court&#8217;s 124 member states would be obligated to arrest Netanyahu and Gallant if they entered those states, the Financial Times <a href="https://www.ft.com/content/0b62f17a-97db-4817-90f8-f98adead79f0">said</a> in a report, adding that the ICC has no means of enforcing this. 
The Details: The court also issued a warrant for Hamas military leader Mohammed Deif. Israeli officials say Deif was killed in an airstrike in Gaza in July. Prosecutors said they issued the warrant because they were not able to confirm whether he is dead or alive. 
The ICC rejected Israel's challenge to the court's jurisdiction over "the situation in the State of Palestine" and over Israeli nationals.
Read Next: <a href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a>
The ICC said in a press release that the arrest warrants are classified as secret, but the chamber decided to release the information since the conduct "appears to be ongoing." The chamber also said it considers it in the best interest of the victims to be aware of the issuance of the warrants. 
Other Developments:  U.S. envoy Amos Hochstein is in Israel for talks with Israeli officials over a cease-fire in Lebanon. Hochstein left Beirut on Wednesday after two days of meetings with Lebanese officials, <a href="https://www.washingtonpost.com/world/2024/11/21/israel-war-news-hamas-gaza-palestine/">according</a> to The Washington Post. 
The United States vetoed a U.N. Security Council resolution put forward Wednesday that called for a cease-fire in Gaza because it was not contingent on the release of hostages still held and it did not condemn Hamas.
At least 44,056 people have been killed in Gaza during the war and 104,268 injured, the Post reported, citing the Gaza Health Ministry. At least 3,558 people have been killed and 15,123 injured in Lebanon, the report said, citing Lebanon&#8217;s health ministry. The organizations do not distinguish between civilians and combatants. 
Israel estimates that approximately 1,200 people were killed in the Oct. 7, 2023 attack and says 377 soldiers have been killed in its military operation in Gaza.
Image: Shutterstock.

Politics

Legal

Global

International Criminal Court Issues Arrest Warrants For Israeli Prime Minister Netanyahu, Gallant For War Crimes

AGFY

Agrify shares are trading lower. The company announced a non-brokered private placement at $22.30 per share for approximately $25.9 million in proceeds.

Barclays analyst Lauren Lieberman maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Overweight and raises the price target from $74 to $79.

BRBR

Barclays Maintains Overweight on BellRing Brands, Raises Price Target to $79

VNET

VNET Group shares are trading higher after the company reported Q3 EPS and revenue that rose year-over-year.

Barclays analyst Brian Morton maintains Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) with a Overweight and raises the price target from C$126 to C$143.

TSX:BMO

Barclays Maintains Overweight on Bank of Montreal, Raises Price Target to C$143

On Wednesday, the FDA granted accelerated approval to Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a href="https://www.benzinga.com/pressreleases/24/11/n42101689/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-a" target="_blank" rel="noreferrer noopener">biliary tract cancer (BTC)</a>.
Ziihera&nbsp;was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41338366/jazz-pharmaceuticals-zepzelcatecentriq-combo-regimen-can-potentially-delay-disease-progression-ex" rel="noreferrer noopener">Jazz Pharmaceuticals&#8217; Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer</a>
The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Regulatory reviews of zanidatamab for BTC remain ongoing in China and Europe.
In late 2022, Zymeworks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) entered into a license and collaboration agreement with Jazz Pharmaceuticals for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia Pacific territories previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">licensed by Zymeworks</a>.
Under the Jazz license and collaboration agreement terms, Zymeworks has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
Zymeworks says the approval represents the first FDA-approved therapy in its pipeline and validates the company&#8217;s Azymetric bispecific platform technology.
Price Action: JAZZ stock closed at $119.24 on Wednesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease" target="_blank" rel="noreferrer noopener">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

JAZZ

ZYME

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Universal Technical Institute shares are trading higher after the company reported better-than-expected Q4 EPS and sales, and provided FY2024 revenue guidance above analyst estimates.

AppLovin shares are trading higher after the company priced a public offering of $3.55 billion in senior notes.

In Anaheim at the recent <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Cannabis Market Spotlight: California </a>event, seasoned cannabis entrepreneur Seth Yakatan shared his perspective on the cannabis industry's current landscape and future potential. 
Despite recent shifts in cannabis stock prices, Yakatan believes the sector remains fundamentally stable. "The technical fundamentals of the sector pretty much remained the same," he noted, adding that he saw the price drop as an opportunity and "just bought more stocks cheaper."
<h4 class="wp-block-heading">Federal Policy and a Cautious Outlook</h4>
Looking ahead, Yakatan discussed the impact of upcoming federal decisions on the cannabis industry. He remains "cautiously optimistic" but believes it could be March before any clear direction emerges. 
Yakatan highlighted three key areas to watch: the selection of a new Attorney General, possibly reclassifying cannabis to Schedule III and ongoing legislative changes in states like Pennsylvania. "Anything other than that's probably just speculation," he remarked, stressing that the path forward depends on these developments.
<h4 class="wp-block-heading">California's Market Leads the Way</h4>
Yakatan also expressed confidence in California's enduring position as a leader in the U.S. cannabis market, calling it "still the biggest cannabis market in the United States." 
Although he acknowledged challenges within California's market, he emphasized the dedication of long-standing businesses that continue to secure investment and make strides in the industry. "I don't see that dynamic changing," Yakatan stated, underscoring his confidence in California's cannabis market to continue thriving.
Yakatan's observations at the event reflected the optimism shared by many industry experts, signaling a resilient future for cannabis even as it faces a complex regulatory environment.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111313/exclusive-fluent-launches-new-cannabis-concentrates-line-for-medical-marijuana-patients-in-florida">FLUENT Launches New Cannabis Concentrates Line For Medical Marijuana Patients In Florida</a></li>
</ul>
Image: AI-Generated Image

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

California's Cannabis Future: Why One Expert Believes The Market Will Hold Strong

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $166 to $163.

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $163

Barclays analyst Alex Scott maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Equal-Weight and raises the price target from $300 to $308.

Barclays Maintains Equal-Weight on Arthur J. Gallagher, Raises Price Target to $308

Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are trading higher on Thursday. The company announced it submitted a <a href="https://www.benzinga.com/pressreleases/24/11/b42099063/super-micro-computer-inc-nasdaq-non-compliance-update">compliance plan to the Nasdaq</a>.
What Happened: After the market close on Wednesday, Super Micro said it submitted a compliance plan to the Nasdaq after receiving a notification letter that it was not in compliance with the Nasdaq&#8217;s timely filing rule. The plan was submitted on Monday with respect to supporting the company&#8217;s request for an extension to regain compliance.
Super Micro said in the compliance plan that it believes it will be able to file both its annual report for the fiscal year ended June, 30 2024 and its quarterly report for the period ended Sept. 30, 2024 within the discretionary period that can be granted by the Nasdaq.
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/42109965/baidus-q3-earnings-revenue-slides-weak-online-ads-market-impact-margins">Baidu&#8217;s Q3 Earnings: Revenue Slides, Weak Online Ads Market Impact Margins</a>
The update comes after the company&#8217;s independent auditor resigned at the end of October over&nbsp;<a href="https://www.benzinga.com/quote/SMCI" target="_blank" rel="noreferrer noopener">governance and transparency concerns</a>. 
Super Micro on Monday announced that it <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42069253/supermicro-stock-is-rising-tuesday-whats-going-on">appointed BDO USA</a> as its new independent auditor, effective immediately.
&#8220;BDO is a highly respected accounting firm with global capabilities.&nbsp;This is an important next step to bring our financial statements current, an effort we are pursuing with both diligence and urgency,&#8221; said&nbsp;Charles Liang, president and CEO of SuperMicro.
Super Micro has faced significant selling pressure since the company&#8217;s auditor raised concerns. The stock traded all the way down to around $17.25 per share last week before bouncing back. Super Micro shares are now up more than 43% over the past five trading sessions.
SMCI Price Action: Super Micro shares were up 5.23% at $27.18 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

SMCI

Super Micro Computer Stock Is Rallying Thursday: What's Going On?

LAZR

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Piper Sandler analyst Adam Butler assumes Farmers National Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMNB#NASDAQ">FMNB</a>) with a Neutral rating and announces Price Target of $17.

Initiation

FMNB

Piper Sandler Assumes Farmers National Banc at Neutral, Announces Price Target of $17

Barclays analyst Alex Scott maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Overweight and raises the price target from $394 to $440.

Barclays Maintains Overweight on Aon, Raises Price Target to $440

Agrify Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) shares are trading lower by 23.9% to $29.50 Thursday morning after the company announced it secured approximately $25.9 million through a <a href="https://www.benzinga.com/pressreleases/24/11/g42108171/agrify-announces-25-9-million-non-brokered-private-placement">non-brokered private placement</a>.
What Happened: The deal, priced at $22.30 per share, involves securities purchase agreements with institutional and accredited investors. The proceeds will support general corporate purposes, including working capital and business development.
The private placement, expected to close on November 21, includes participation from Chairman and Interim CEO Benjamin Kovler, who purchased 10,000 shares at $38.76 each in accordance with Nasdaq requirements.
Kovler emphasized the strategic significance of the funding, calling it a &#8220;strong move&#8221; for the company and shareholders. &#8220;We plan to channel this capital into areas within our expertise to maximize shareholder value,&#8221; he said, highlighting optimism around cannabis and hemp consumer trends. 
Kovler also confirmed progress on the company&#8217;s pending Señorita transaction, which is anticipated to close by year-end.
Read Also: <a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a>
<h2 class="wp-block-heading">Should I Sell My AGFY Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
AGFY has a 52-week high of $42.00 and a 52-week low of $2.71.

Why Agrify (AGFY) Stock Is Getting Hammered

CGNT

Cognyte Secures $2M+ Follow-On Order From Leading North American Law Enforcement Agency, Bringing Total Investment To $3M As Agency Replaces Incumbent Provider For Enhanced Threat Detection And Operational Intelligence

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bullfrog AI Hldgs (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfrg-stock-quote/">BFRG</a>) just reported results for the first quarter of 2024.<ul><li>Bullfrog AI Hldgs reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bfrg-stock-earnings-bullfrog-ai-hldgs-for-q1-of-2024/">BFRG Stock Earnings: Bullfrog AI Hldgs Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BFRG Stock Earnings: Bullfrog AI Hldgs Reported Results for Q1 2024

BullFrog AI Holdings, Inc. (BFRG) has issued an announcement. Bullfrog AI Holdings, Inc. has recently shared a press release, providing valuable in...

BullFrog AI Holdings Releases Key Investor Insights

BullFrog AI Holdings, Inc. (BFRG) has provided an update. Bullfrog AI Holdings, Inc. announced a significant update on July 25, 2024, and has relea...

BullFrog AI Holdings Unveils Major Update to Investors

BullFrog AI Holdings, Inc. ( ($BFRG) ) has issued an update. Bullfrog AI Holdings, Inc. has released promising research data for its liver disease ...

BullFrog AI's BF-114 Shows Promise in Liver Disease Treatment

BullFrog AI Holdings, Inc. ( ($BFRG) ) just unveiled an update. BullFrog AI has appointed Dr. John Baldoni, a seasoned expert with over four decade...

BullFrog AI Strengthens Board with Pharma Expert

Bullfrog AI announces pricing of offering and private placement for proceeds of $3.13M

BullFrog AI (BFRG) Holdings announced that it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of...

Bullfrog AI announces closing of registered direct offering, private placement

BullFrog AI (BFRG), announced its VP Artificial Intelligence, Enrique Garcia-Rivera, Ph.D., will present at Google's inaugural Cancer AI Symposium ...

Bullfrog AI to present at Google's Cancer AI Symposium

Bullfrog AI Holdings files secondary offering of common stock underlying warrants

Issuable upon exercise of common stock purchase warrants. Also files to sell 62.6M shares of common stock for holders underlying placement agent wa...

Bullfrog AI files to sell 1.565M shares of common stock for holders

Press Releases

Join BullFrog AI's Exclusive Live Investor Webinar and Q&A Session on June 12

BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets

BullFrog AI to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114

Management

BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million

Offerings

WallachBeth Capital Announce Pricing of Bullfrog AI's Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million

Bullfrog AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million

WallachBeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million

BullFrog AI's VP Artificial Intelligence to Present at Google's Cancer AI Symposium

Comments

Bullfrog AI Hldgs

Bullfrog AI Hldgs (BFRG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga